Three new eudesmane sesquiterpenoids and a new dimer from the aerial part of Salvia plebeia R. Br.

Publication date: June 2018 Source:Phytochemistry Letters, Volume 25 Author(s): Lie-Feng Ma, Hong Xu, Ji-Dong Wang, Xiang-Min Tong, Zha-Jun Zhan, You-Min Ying, Jian-Wei Wang, Hui Zhang, Wei-Guang Shan Four new compounds, including three eudesmane sesquiterpenoids (1–3) and a dimeric sesquiterpenoid lactone (4), were isolated from the aerial part of Salvia plebeia R. Br., together with two known eudesmanolides (5–6). Their structures were elucidated by extensive spectroscopic analysis including 1D and 2D NMR, HR-ESI–MS spectra. Antiproliferative activities of isolates against six human myeloid leukemia cell lines were evaluated, salplebeone D (1) and G (4) showed moderate inhibitory activity. In addition, compound 4 was a rare eudesmane sesquiterpenoid dimer obtained from this specie for the first time.
Source: Phytochemistry Letters - Category: Chemistry Source Type: research

Related Links:

Authors: Ciftciler R, Haznedaroglu IC, Ozcebe O, Aksu S, Sayınalp N, Goker H, Demiroglu H, Buyukasık Y Abstract Background and Aim: Recently, acute promyelocytic leukemia (APL) has shifted from the most hazardous to the best curable type of acute myeloid leukemia. Anthracyclines, all-trans retinoic acid (ATRA) and arsenic derivatives are the most important developments for the treatment of APL. ATRA promotes the terminal differentiation of malignant promyelocytes to mature neutrophils. We aimed to compare platelet and neutrophil recovery time after induction chemotherapy in patients with acute myeloid leukemia (A...
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
ConclusionWhen performed adequately, CNB is a good substitute to SEB. Strict and specific guidelines need to be updated and adopted to direct on how and when it can be used, including the recommendation of concomitant complementary diagnostic laboratory testing such as flow cytometry. The latter should be readily available in order not to compromise the quality and the accuracy of the rendered diagnoses.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The objective of this analysis was to describe the association between white blood cell (WBC) levels and occurrence of thrombotic events among patients with PV from a large real-world population.Patients and MethodsThis retrospective analysis using Veterans Health Administration claims data (October 1, 2005, to September 30, 2012) evaluated adult patients assigned to 4 WBC categories (WBC
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Mariana Koehler, Filipa Moita, José Cabeçadas, Maria Gomes da Silva
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOfficial titles are more informative than short titles on clinicaltrials.gov. However, both short and official titles often lack basic information needed to understand a clinical trial. This has persisted despite updates to the platform. These results highlight the need for standardization of format and content in study titles.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study aimed to determine the impact of treatment facility on overall survival outcomes in DLBCL patients stratified by IPI risk groups.MethodsThe National Cancer Database was utilized to identify patients diagnosed with DLBCL between 2004 and 2015. Patients were stratified by IPI risk score from low to high risk disease, and overall survival of those treated at academic centers were compared to those treated at non-academic centers.ResultsTreatment at academic centers was associated with a significantly improved overall survival for all DLBCL patients (108.3 months) when compared to non-academic centers (74.5 months, p
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: November 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 11Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: November 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 11Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Leukemia